Latest filing published 29 Oct 2026 for Veraxa Biotech AG - Post de-SPAC, €760.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Marc Gruninger: trading record in brief
This profile gathers the share dealings of Marc Gruninger in Veraxa Biotech AG - Post de-SPAC. Between 27 October 2026 and 28 October 2026, the trades on record add up to 2 filings.
No open-market sale appears; the market trades are 2 purchases worth €8,967. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
On 29 October 2026 came the latest disclosure, an open-market purchase for €760 in Veraxa Biotech AG - Post de-SPAC. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Marc Gruninger
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 867 shares@ US$0.98Ordinary SharesSEC:0001829126-26-011778:0Canonical exit: 25 Jan 2027 (T+90)
- 9,133 shares@ US$1.00Ordinary SharesSEC:0001829126-26-011778:1Canonical exit: 26 Jan 2027 (T+90)
2 of 2 declarations